• linkedin
  • Increase Font
  • Sharebar

    Aflibercept shows macular perfusion gains in VISTA subanalysis

    Diabetic macular edema (DME) patients with baseline macular nonperfusion had more advanced disease. When comparing treatments in those patients, aflibercept (Eylea, Regeneron Pharmaceuticals) led to a greater improvement in macular perfusion status as well as visual and anatomic improvement by week 100.

    The post-hoc analysis came from the VIVID and VISTA trials, which were 2 parallel, phase III, randomized, multicenter, double-masked trials in patients with clinically significant DME, according to Dilsher S. Dhoot, MD, Retina Consultants, Santa Barbara, CA.

    Patients had central involvement and an ETDRS best-corrected visual acuity of 20/40 to 20/320. Patients were randomized to receive 1 of 2 different dosings schedules of aflibercept or they were part of a control arm receiving a laser treatment. The study continued through week 148.



    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Latest Tweets Follow

    var script= ' ';